Table 3.
Genetic abnormalities identified (safety set)
| Genetic abnormality | Treatment-naïve patients, n (%) (n = 248) | Pretreated patients, n (%) (n = 64) |
|---|---|---|
| Complete absence of 1 sex chromosome (karyotype 45,X) | 89 (31.3) | 26 (40.6) |
| Mean (SD) age at rhGH treatment start, years | 8.52 (4.61) | 7.15 (4.44) |
| Mean (SD) target height SDS | 0.01 (0.75) | −0.27 (0.73) |
| Mean (SD) rhGH (Omnitrope®) dose at baseline, μg/kg/day | 39.3 (11.4) | 44.2 (8.3) |
| Mosaicism (karyotype 45,X/46,XX) | 78 (27.5) | 13 (20.3) |
| Mean (SD) age at rhGH treatment start, years | 8.08 (3.58) | 5.74 (2.50) |
| Mean (SD) target height SDS | −0.15 (0.72) | −0.35 (0.60) |
| Mean (SD) rhGH (Omnitrope®) dose at baseline, μg/kg/day | 38.6 (9.8) | 43.5 (7.8) |
| Partial absence of 1 sex chromosome (karyotype 45,X/46,X,delX) | 16 (5.6) | 5 (7.8) |
| Mean (SD) age at rhGH treatment start, years | 10.17 (4.41) | 6.78 (3.74) |
| Mean (SD) target height SDS | −0.10 (1.37) | −0.01 (0.66) |
| Mean (SD) rhGH (Omnitrope®) dose at baseline, μg/kg/day | 40.5 (10.9) | 38.3 (10.4) |
| Structural aberrations (karyotype 45,X/46,X,rX) | 12 (4.2) | 2 (3.1) |
| Mean (SD) age at rhGH treatment start, years | 7.84 (4.65) | 3.72 (1.02) |
| Mean (SD) target height SDS | 0.02 (0.73) | −0.34 (0.44) |
| Mean (SD) rhGH (Omnitrope®) dose at baseline, μg/kg/day | 41.8 (14.2) | 50.0 (N/A) |
| Others | 72 (25.4) | 14 (21.9) |
| Mean (SD) age at rhGH treatment start, years | 8.82 (4.28) | 6.30 (3.98) |
| Mean (SD) target height SDS | 0.10 (0.67) | −0.07 (0.49) |
| Mean (SD) rhGH (Omnitrope®) dose at baseline, μg/kg/day | 36.4 (10.4) | 41.5 (12.4) |
| Missing information | 17 (6.0) | 4 (6.3) |
rhGH, recombinant human growth hormone.